Tesamorelin Research FAQ

Q: What is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH). Its sequence is identical to the full-length human GHRH(1-44), with the addition of a *trans*-3-hexenoic acid group at the N-terminus. That modification was investigated specifically to improve resistance to enzymatic degradation in plasma — native GHRH is rapidly cleaved by the enzyme DPP-4, and the hexenoyl modification confers substantially greater plasma stability [1, 2]. In a research context, Tesamorelin is studied as a GHRH-receptor agonist that activates pituitary somatotroph cells to release endogenous growth hormone. Research use only. Not for human consumption.

Q: Is Tesamorelin FDA-approved?

Yes — but for one specific, narrowly defined indication only. The U.S. Food and Drug Administration approved Tesamorelin (brand name Egrifta) for the treatment of HIV-associated lipodystrophy, specifically excess abdominal fat accumulation in adults with HIV [3]. That approval is based on two Phase III randomized controlled trials conducted in that patient population. It does not extend to weight management, general body composition changes, anti-aging, or any other use. All other investigational contexts for Tesamorelin remain outside of any regulatory approval.

Q: How does Tesamorelin interact with the GHRH receptor?

Published pharmacological research describes Tesamorelin binding to the pituitary GHRH receptor — a seven-transmembrane Gs protein-coupled receptor located on somatotroph cells in the anterior pituitary. Receptor engagement activates intracellular cAMP signaling, which triggers the synthesis and pulsatile release of endogenous growth hormone [1, 2]. A study in healthy men documented that daily Tesamorelin administration augmented both basal and pulsatile GH secretion over a two-week period, with IGF-1 rising significantly as a downstream response [4]. These are laboratory and clinical measurements in a specific studied population — they describe what researchers observed in controlled conditions.

Q: What is the relationship between Tesamorelin and IGF-1?

Growth hormone released by the pituitary in response to Tesamorelin travels to the liver, where it stimulates hepatic production of insulin-like growth factor-1 (IGF-1). IGF-1 is a downstream mediator in the GH axis and has its own receptor system in peripheral tissues. In the Tesamorelin clinical literature, IGF-1 has been used as a pharmacodynamic biomarker — measurable evidence that the compound engaged its target. Researchers have also noted that the GHRH-receptor pathway, unlike direct exogenous GH administration, preserves the normal IGF-1 negative feedback on pituitary GH secretion, which is cited as a theoretical mechanistic distinction [2, 4].

Q: How does Tesamorelin differ from Sermorelin and CJC-1295?

All three are GHRH-receptor agonists, but they differ structurally and pharmacokinetically:

• Sermorelin is the shortest of the three — GHRH(1-29), the minimal sequence with full receptor-binding activity. It has a short plasma half-life due to DPP-4 susceptibility [5].
• Tesamorelin carries the full 44-amino-acid GHRH sequence plus a hexenoyl N-terminal modification that improves DPP-4 resistance, giving it greater plasma stability than Sermorelin [6].
• CJC-1295 is also GHRH(1-29) but incorporates DAC (drug affinity complex) technology — a maleimide moiety that covalently binds circulating albumin after injection, dramatically extending its half-life to an estimated 5.8–8.1 days per published research [7].

The analytical detection literature has confirmed these are distinct compounds with different plasma degradation profiles and mass-spectrometry signatures [6]. See our [full comparison article](/blog/tesamorelin-vs-cjc-sermorelin) and [CJC-1295 research overview](/research/cjc-1295) for more detail.

Q: What has published research investigated regarding Tesamorelin and liver fat?

A randomized, double-blind, multicenter trial (Mallon et al., Lancet HIV, 2020) investigated Tesamorelin in HIV-infected adults with nonalcoholic fatty liver disease (NAFLD) — a population with a substantially elevated NAFLD prevalence (estimated 30–40%) [8]. The study reported reductions in liver fat and findings related to fibrosis markers over one year in that specific population. A separate publication described transcriptomic changes in hepatic gene expression in HIV-associated NAFLD following Tesamorelin administration [9]. These findings are in an HIV-positive population under specific trial conditions; they describe what researchers observed in that context, not a general statement about liver effects.

Q: Has Tesamorelin been studied in the context of cognitive function?

Exploratory research has investigated GHRH-analog administration (including Tesamorelin) alongside cognitive testing and brain neurochemistry measurement. A controlled trial (Baker et al., Arch Neurol, 2012) examined 20 weeks of GHRH-analog administration in adults with mild cognitive impairment and healthy older adults, reporting favorable scores on cognitive assessments in both groups [10]. A related study used magnetic resonance spectroscopy to measure brain γ-aminobutyric acid (GABA) levels during GHRH-analog treatment [11]. A more recent study in people with HIV and abdominal obesity reported a trend toward improved neurocognitive performance in the Tesamorelin group after 6 months, though the between-group difference did not reach statistical significance [12]. These are early, exploratory findings — they describe what researchers measured in specific populations and do not establish that Tesamorelin improves cognitive function.

Q: What does "research use only / not for human consumption" mean?

It means that Tesamorelin supplied through Obsessed Living is intended exclusively for laboratory research purposes — characterizing the compound, conducting in-vitro studies, and related scientific investigation. It is not supplied for personal use, self-administration, or any clinical application outside of a lawfully authorized healthcare context. The compound is not an approved drug for the indications researchers are actively investigating beyond HIV-associated lipodystrophy.

Q: Where can I read the underlying studies?

All citations in this content cluster link to PubMed (pubmed.ncbi.nlm.nih.gov) and PMC (pmc.ncbi.nlm.nih.gov) — the NIH's publicly accessible research databases. Every citation used in this cluster corresponds to a real, retrievable publication; none have been fabricated or approximated.

Return to the [Tesamorelin research overview](/research/tesamorelin) for the full pillar.